New drug PIT565 enters human testing for rheumatoid arthritis
NCT ID NCT07029555
First seen Jun 27, 2026 · Last updated Jul 01, 2026 · Updated 2 times
Summary
This early-phase trial is testing a new drug, PIT565, in 57 adults with rheumatoid arthritis. The main goal is to check if the drug is safe and how the body processes it. Researchers will monitor side effects and measure drug levels in the blood.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
PIT565
What this could lead to
If this early trial shows PIT565 is safe and tolerable, it could lead to larger studies testing whether it helps control rheumatoid arthritis symptoms.
What could go wrong
This is a very early phase 1 trial with only 57 people, focused on safety, not effectiveness. The drug may not work or could have side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RHEUMATOID ARTHRITIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Novartis Investigative Site
Pilar, Buenos Aires, B1629AHJ, Argentina
-
Novartis Investigative Site
CABA, C1181ACH, Argentina
-
Novartis Investigative Site
Sofia, 1618, Bulgaria
-
Novartis Investigative Site
Beijing, 100191, China
-
Novartis Investigative Site
Beijing, 100730, China
-
Novartis Investigative Site
Brest, 29200, France
-
Novartis Investigative Site
Le Kremlin-Bicêtre, 94275, France
-
Novartis Investigative Site
Paris, 75014, France
-
Novartis Investigative Site
Jena, Thuringia, 07740, Germany
-
Novartis Investigative Site
Mainz, 55131, Germany
-
Novartis Investigative Site
Szeged, 6725, Hungary
-
Novartis Investigative Site
Leiden, South Holland, 2333 CL, Netherlands
-
Novartis Investigative Site
Cluj-Napoca, Cluj, 400006, Romania
-
Novartis Investigative Site
Bucharest, 011658, Romania
-
Novartis Investigative Site
Santiago Compostela, A Coruna, 15706, Spain
-
Novartis Investigative Site
Barcelona, 08035, Spain